FY2025 Earnings Forecast for CVKD Issued By Zacks Research

Cadrenal Therapeutics, Inc. (NASDAQ:CVKD) – Zacks Research issued their FY2025 earnings per share estimates for shares of Cadrenal Therapeutics in a report issued on Wednesday, February 25th. Zacks Research analyst D. Bautz anticipates that the company will post earnings per share of ($6.35) for the year. The consensus estimate for Cadrenal Therapeutics’ current full-year earnings is ($7.59) per share. Zacks Research also issued estimates for Cadrenal Therapeutics’ Q4 2025 earnings at ($1.12) EPS, FY2026 earnings at ($3.00) EPS and FY2027 earnings at ($2.36) EPS.

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Cadrenal Therapeutics in a report on Wednesday, January 21st. One investment analyst has rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $32.00.

Cadrenal Therapeutics Trading Down 2.9%

Shares of CVKD stock opened at $8.38 on Friday. Cadrenal Therapeutics has a twelve month low of $4.91 and a twelve month high of $21.70. The stock has a fifty day simple moving average of $7.02 and a two-hundred day simple moving average of $10.47. The stock has a market capitalization of $19.61 million, a price-to-earnings ratio of -1.05 and a beta of 1.18.

Insider Activity at Cadrenal Therapeutics

In related news, CFO Matthew K. Szot sold 9,933 shares of the company’s stock in a transaction on Monday, December 29th. The stock was sold at an average price of $6.97, for a total transaction of $69,233.01. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 26.09% of the company’s stock.

Hedge Funds Weigh In On Cadrenal Therapeutics

A number of large investors have recently added to or reduced their stakes in CVKD. DRW Securities LLC purchased a new stake in shares of Cadrenal Therapeutics during the fourth quarter valued at about $171,000. Geode Capital Management LLC grew its position in shares of Cadrenal Therapeutics by 14.3% in the 4th quarter. Geode Capital Management LLC now owns 14,528 shares of the company’s stock worth $98,000 after buying an additional 1,818 shares during the last quarter. JPMorgan Chase & Co. bought a new position in shares of Cadrenal Therapeutics during the 3rd quarter worth approximately $103,000. Finally, Citadel Advisors LLC purchased a new stake in Cadrenal Therapeutics during the third quarter valued at approximately $274,000. 7.92% of the stock is currently owned by institutional investors.

About Cadrenal Therapeutics

Cadrenal Therapeutics, Inc operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel oral and reversible anticoagulant to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation, such as patients with left ventricular assist devices, end-stage kidney disease, atrial fibrillation, and thrombotic anti-phospholipid syndrome. Cadrenal Therapeutics, Inc was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.